Shares of ImmuPharma plc (LON:IMM – Get Free Report) were down 8.2% during mid-day trading on Wednesday . The company traded as low as GBX 4.30 ($0.05) and last traded at GBX 4.59 ($0.06). Approximately 7,105,372 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 22,291,344 shares. The stock had previously closed at GBX 5 ($0.06).
ImmuPharma Trading Down 8.3 %
The company has a market capitalization of £19.10 million, a P/E ratio of -458.70 and a beta of 1.53. The business’s 50-day simple moving average is GBX 2.28 and its 200 day simple moving average is GBX 1.89.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Must-Have ETFs Set to Dominate This Quarter
- The 3 Best Retail Stocks to Shop for in August
- Seeking Stability? These 3 Stocks Offer Strong Potential
- ETF Screener: Uses and Step-by-Step Guide
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
